Mumbai Shortlists Nine Potential Vaccine Suppliers But There May Be A Problem
Mumbai's bid to directly procure one crore vaccines for city residents may face a hurdle even as the administration of India's financial capital shortlisted nine suppliers for further scrutiny.
“Ten potential suppliers had responded to the global expression of interest. Out of that, one has already withdrawn," the Brihanmumbai Municipal Corporation said in its statement. "Documents submitted by the nine suppliers will be scrutinized in the next two-three days.”
Of these, seven have expressed interest in supplying Russian vaccine Sputnik V, while one has offered to provide Sputnik Light Covid vaccine, the civic authority said. Another has shown interest in supplying one of the approved vaccines, it said, without giving details.
Meaning, most of the interested suppliers are banking on the Sputnik V vaccine. That comes when Dr. Reddy's Laboratories Ltd., in a joint statement with Russian Direct Investment, has said that it is the brand custodian of Sputnik V in India and has the sole distribution rights for the first 250 million (25 crore) doses—first and second shot included. The company, which will first import and later manufacture locally, has warned of potential "fraud" by unauthorised individuals offering "fake" procurement deals for Sputnik.
The Mumbai civic corporation, in its statement, said it will examine the business relationship between the interested suppliers and the companies that actually make the vaccines.
Joint statement by @rdif_press and @drreddys on the @sputnikvaccine in India.#DrReddys pic.twitter.com/rB7pEApKvV
May 28, 2021The BMC had on May 12 floated the EOI to buy 1 crore Covid-19 vaccines for people living or working within Mumbai's municipal limits. The final date of submitting the proposal was extended from May 18 to first May 25 and then June 1. The move came after the central government opened inoculation to the 18-44 age group but put the procurement onus on states at a time the nation faces a shortage of jabs.
The BMC had also received a bid for supplying vaccines by Pfizer and AstraZeneca-Oxford (made and marketed in India by the Serum Institute of India as Covishield) but it was withdrawn later.
India has approved three vaccines—Covishield, Covaxin by Bharat Biotech Ltd. and Sputnik V. As of May 31, the BMC has administered more than 30.4 lakh Covishield and over 23.6 lakh doses of Covaxin.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.